Consequently, the integration of PD-1/PD-L1 inhibitor therapy with other pharmacological regimens to enhance the adverse effects of PD-1/PD-L1 inhibitors has emerged as a prominent area of focus in tumor therapy. This evidence concerns the gene CD274 and neoplasm.